Related Experiment Video
Updated: Jan 10, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
Development of a Polymeric TAVR Device Tailored to Bicuspid Aortic Valve Patients Using In Silico Design Optimization
Kyle Baylous1, Ryan Helbock1, Brandon Kovarovic1
1Department of Biomedical Engineering, Stony Brook University, T8-050 Health Sciences Center, Stony Brook, NY, 11794-8084, USA.
Purpose:
Bicuspid aortic valve (BAV), the most common congenital heart defect, affects ~ 2% of the population but accounts for nearly half of aortic stenosis (AS) cases, typically emerging 10-20 years earlier than in tricuspid aortic valve (TAV) patients. Current tissue-based transcatheter aortic valve replacement (TAVR) devices are designed for TAV anatomy and merely approved for BAV, leading to poor annular fit, paravalvular leak, thrombosis, and limited durability-especially problematic for younger BAV patients. This study presents PolyV-B, a first-of-its-kind polymeric TAVR device tailored to BAV anatomy, aimed at improving durability, hemodynamics, and outcomes through advanced computational modeling.
Methods:
PolyV-B features a sutureless, eccentric valve with asymmetric xSIBS polymeric leaflets and a fatigue-optimized nitinol stent with a centerline groove. The 29-mm device incorporates a rhombic stent profile and large cells to enhance anchoring and coronary access. Developed on the 3DExperience platform, it was virtually deployed in six patient-specific BAV anatomies. Its performance was compared to the Evolut R using finite element modeling and fluid-structure interaction (FSI) simulations.
Results:
Simulations demonstrated that PolyV-B offers a 50% strain reduction during crimping, improved annular fit, enhanced sealing, and reduced thrombogenic risk. Flow simulations confirmed superior hemodynamics and a larger orifice area compared to Evolut R.
Conclusion:
The PolyV-B TAVR device introduces design innovations that enhance durability, hemodynamics, and usability. Simulations in six patient-specific BAV anatomies demonstrated advantages over the Evolut R device. Optimization enabled efficient feasibility assessment, supporting the development of a tailored, clinically impactful solution for the BAV patient population facing unmet clinical needs.
More Related Videos
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
06:56Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies
Published on: August 25, 2023